Results 61 to 70 of about 655,557 (182)
Smart Molecules, EarlyView.AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin +10 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard +2 more
wiley +1 more source
The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity
, 2004 LFM-A13, or alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide, was shown to inhibit Bruton's tyrosine kinase (Btk). Here we show that LFM-A13 efficiently inhibits erythropoietin (Epo)-induced phosphorylation of the erythropoietin ...
van den Akker, E (Emile) +12 more
core +1 more source
British Journal of Haematology, EarlyView.Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2
Haematologica, 2020 Inhibitors of the tyrosine kinase Btk have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in ...
Phillip L.R. Nicolson +19 more
doaj +1 more source
British Journal of Haematology, EarlyView.After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan +8 more
wiley +1 more source
Integrin Signaling Shaping BTK-Inhibitor Resistance
, 2022 Integrins are adhesion molecules that function as anchors in retaining tumor cells in supportive tissues and facilitating metastasis. Beta1 integrins are known to contribute to cell adhesion-mediated drug resistance in cancer. Very late antigen-4 (VLA-4),
Laura Polcik +11 more
core +1 more source
Exploitation of Bruton’s kinase (BTK) pathway in malignant diseases
, 2021 The important role of BTK pathway in many processes associated with malignancies has been undoubtedly proven. BTK was linked to many B cell malignancies.
Nawaiseh, Mohammad Yahya Suleiman
core
Second-generation inhibitors of Bruton tyrosine kinase
Journal of Hematology & Oncology, 2016 Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu +3 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari +28 more
wiley +1 more source